Overview

"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma
Phase:
PHASE1
Details
Lead Sponsor:
Mingzhi Zhang